ABUS vs USB
Arbutus Biopharma Corp (ABUS) versus U.S. Bancorp (USB) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
U.S. Bancorp (USB) is a banks - regional company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported USB revenue for 2025-12-31 was $28.66B. Net income was $7.57B. Revenue was up 4.4% from 2024-12-31 to 2025-12-31. USB currently screens at market cap $74.68B and trailing P/E 11.9.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. USB currently screens at market cap $74.68B and trailing P/E 11.9.
Not investment advice. Open the ABUS and USB stock pages for the full models.
Not investment advice.